AAAAAA
Results:
1-10
|
Results: 10
Authors:
Wu-Pong, S
Citation: S. Wu-pong, Alternative interpretations of the oligonucleotide transport literature: insights from nature, ADV DRUG DE, 44(1), 2000, pp. 59-70
Authors:
Broaddus, WC
Prahbu, SS
Wu-Pong, S
Gillies, GT
Fillmore, H
Citation: Wc. Broaddus et al., Strategies for the design and delivery of antisense oligonucleotides in central nervous system, METH ENZYM, 314, 2000, pp. 121-135
Authors:
Tam, RC
Wu-Pong, S
Pai, B
Lim, C
Chan, A
Thomas, DF
Milovanovic, T
Bard, J
Middleton, PJ
Citation: Rc. Tam et al., Increased potency of an aptameric G-rich oligonucleotide is associated with novel functional properties of phosphorothioate linkages, ANTISENSE N, 9(3), 1999, pp. 289-300
Authors:
Jarvis, MAE
Wu-Pong, S
Kniseley, JS
Schnoll, SH
Citation: Mae. Jarvis et al., Alterations in methadone metabolism during late pregnancy, J ADDICT D, 18(4), 1999, pp. 51-61
Authors:
Wu-Pong, S
Schnoll, S
Weaver, M
Citation: S. Wu-pong et al., Butorphanol pharmacokinetics in a CRPS patient, J PAIN SYMP, 17(1), 1999, pp. 1-2
Authors:
Wu-Pong, S
Livesay, V
Dvorchik, B
Barr, WH
Citation: S. Wu-pong et al., Oligonucleotide transport in rat and human intestine ussing chamber models, BIOPHARM DR, 20(9), 1999, pp. 411-416
Authors:
Wu-Pong, S
Cheng, CK
Citation: S. Wu-pong et Ck. Cheng, Pharmacokinetic simulations using cellular automata in a pharmacokinetics course, AM J PHAR E, 63(1), 1999, pp. 52-55
Authors:
Wu-Pong, S
Citation: S. Wu-pong, An overview of biotechnology, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, 1999, pp. 1-19
Authors:
Wu-Pong, S
Citation: S. Wu-pong, Treatment options, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, 1999, pp. 51-68
Authors:
Lysik, M
Wu-Pong, S
Citation: M. Lysik et S. Wu-pong, Oligonucleotides and ribozymes, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, 1999, pp. 143-185
Risultati:
1-10
|